New Data Presented at IDWeek 2024 Show Adjuvanted and High-Dose Influenza Vaccines are Comparable in Protecting Adults 65 Years of Age and Older Against Seasonal Influenza
CSL LTD SP/ADR (CSLLY)
NASDAQ:AMEX Investor Relations:
csl.com/investors
Company Research
Source: PR Newswire
Results of the first season of a randomized study showed adjuvanted and high-dose influenza vaccines did not differ in effectiveness against PCR-confirmed influenza.This is the first randomized study to evaluate the relative vaccine effectiveness of adjuvanted influenza vaccines compared to high-dose influenza vaccines for prevention of lab-confirmed influenza.SUMMIT, N.J., Oct. 18, 2024 /PRNewswire/ -- CSL Seqirus, a business of CSL (ASX: CSL), today announced the first season (2023-2024 influenza season) results of the first pragmatic randomized study to evaluate the relative vaccine effectiveness (rVE) of adjuvanted inactivated influenza vaccine (aIIV) compared to high-dose inactivated influenza vaccine (HD-IIV) for prevention of lab-confirmed influenza. Results for the first season demonstrated that adjuvanted and high-dose influenza vaccines did not differ in effectiveness against Polymerase Chain Reaction (PCR)-confirmed influenza with a rVE of aIIV vs HD-IIV of 1.5% (95% confid
Show less
Read more
Impact Snapshot
Event Time:
CSLLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CSLLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CSLLY alerts
High impacting CSL LTD SP/ADR news events
Weekly update
A roundup of the hottest topics
CSLLY
News
- Transforming pharmaceutical R&D: the impact of digital technologies on drug discovery and development [Yahoo! Finance]Yahoo! Finance
- CSL Seqirus Presents Data at IDWeek 2024 Highlighting the Urgent Need to Increase Influenza Vaccination Rates and the Benefits of Cell-Based Influenza VaccinesPR Newswire
- Pharmanovia Acquires Exclusive Rights to Treatment for Parkinson’s DiseaseBusiness Wire
- CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Sixth BARDA Award in Response to Avian InfluenzaPR Newswire
- CSL Seqirus Presents Real-World Evidence at OPTIONS XII Conference Highlighting Effectiveness of Influenza VaccinationsPR Newswire